Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2018 Nov 5;6:118. doi: 10.1186/s40478-018-0622-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 1 — Radiologic findings. a (T1-Weighted Postcontrast and T2-Weighted Axial Magnetic Resonance Imaging), Large right inferomedial temporal solid-multicystic mass with a postcontrast enhancing component. b (T1-Weighted Pre and Postcontrast Axial Magnetic Resonance Imaging), Three-month postoperative leptomeningeal spread involving the upper brainstem. c (T1-Weighted Pre and Postcontrast Axial Magnetic Resonance Imaging), Eight-month postoperative progression of leptomeningeal involvement despite standard chemotherapy. d (T1-Weighted Pre and Postcontrast Axial Magnetic Resonance Imaging), Fourteen-month postoperative decrease in residual tumor after 6 months of BRAF-MEK inhibitor therapy